Pearl River Capital’s Immunomedics Inc IMMU Stock Holding History

Pearl River Capital’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,658	Closed	-$66K	–	948
2018 Q4	$66K	Buy	+4,658	New	+$92.5K	0.3%	94

Other funds holding IMMU

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pearl River Capital's IMMU Position: Q1 2019 in Review

Pearl River Capital sold out of Immunomedics Inc (IMMU) in Q1 2019, closing a stake of 4,658 shares — an estimated $66K sold.

Pearl River Capital first reported a position in IMMU in Q4 2018 and held it in 1 quarter. The position peaked at $66K in Q4 2018. 204 funds tracked by Wall St. Rank hold IMMU as of Q1 2019.

Pearl River Capital reported no remaining Immunomedics Inc position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 4,658 Immunomedics Inc shares in Q1 2019, an estimated $66K.
Pearl River Capital first reported a position in Immunomedics Inc in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Immunomedics Inc position peaked at $66K in Q4 2018.
204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.